{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:10:38Z","timestamp":1778285438659,"version":"3.51.4"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":302,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.ctarc.2020.100232","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T02:46:20Z","timestamp":1604371580000},"page":"100232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes"],"prefix":"10.1016","volume":"25","author":[{"given":"Paul","family":"Markowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malini","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Groisberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Aisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma K.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhajyoti","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shridar","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2020.100232_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008","volume":"19","author":"Henley","year":"2013","journal-title":"Int. J. Occup. Environ. Health"},{"issue":"14","key":"10.1016\/j.ctarc.2020.100232_bib0002","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol"},{"issue":"10026","key":"10.1016\/j.ctarc.2020.100232_bib0003","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctarc.2020.100232_bib0004","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctarc.2020.100232_bib0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J. Transl. Med"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100232_bib0006","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100232_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2020.100232_bib0008","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1200\/JCO.2019.37.15_suppl.8552","article-title":"Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy","volume":"37","author":"Zauderer","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100232_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"10","key":"10.1016\/j.ctarc.2020.100232_bib0010","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J. Thorac. Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2020.100232_bib0011","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir. Med"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2020.100232_bib0012","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2018.36.15_suppl.8503","article-title":"DREAM: a phase II study of durvalumab with first line chemotherapy in mesothelioma\u2014first results","volume":"36","author":"Nowak","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:12Z","timestamp":1762842132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220300678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":12,"alternative-id":["S2468294220300678"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100232","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100232"}}